Rimegepant

Rimegepant is an innovative medication being studied for the treatment of migraine headaches. Clinical trials are exploring its effectiveness for both acute migraine relief and prevention of frequent migraines in adults and adolescents. This article summarizes key findings from recent clinical trials investigating rimegepant’s potential benefits and safety profile for migraine patients.

Table of Contents

What is Rimegepant?

Rimegepant is a medication used for treating migraines. It belongs to a class of drugs called gepants, which are small molecules that block a specific protein in the body called calcitonin gene-related peptide (CGRP) receptor[1]. Rimegepant is also known by other names, including PF-07899801, BHV-3000, and Nurtec ODT[2][3].

What Conditions Does Rimegepant Treat?

Rimegepant is primarily used for the treatment of migraine headaches. It has been studied for use in various types of migraines, including:

  • Episodic migraine: Migraines that occur less frequently, typically less than 15 days per month[4]
  • Chronic migraine: Migraines that occur 15 or more days per month[5]
  • Menstrual migraine: Migraines that are related to a woman’s menstrual cycle[6]
  • Migraine with aura: Migraines that are preceded by sensory disturbances such as visual changes[1]

Additionally, some research is exploring the use of rimegepant for cluster headaches, which are extremely painful headaches that occur in cycles or clusters[3].

How Does Rimegepant Work?

Rimegepant works by blocking the CGRP receptor in the body. CGRP is a protein that is involved in pain signaling and inflammation in the brain. By blocking this receptor, rimegepant can help to reduce the pain and other symptoms associated with migraines[1].

How is Rimegepant Administered?

Rimegepant is typically administered as an orally disintegrating tablet (ODT). This means that the tablet dissolves quickly when placed on or under the tongue, making it easy to take without water. The usual dose is 75 mg[5][2].

Rimegepant can be used in two main ways:

  1. Acute treatment: Taking the medication when a migraine attack begins to relieve symptoms[7]
  2. Preventive treatment: Taking the medication regularly (often every other day) to reduce the frequency of migraine attacks[5]

Effectiveness of Rimegepant

Clinical trials have shown that rimegepant can be effective for both acute treatment and prevention of migraines. Some key findings include:

  • Reduction in the number of migraine days per month[5]
  • Improvement in pain relief within 2 hours of taking the medication[7]
  • Decrease in the use of other acute migraine medications[5]
  • Improvement in quality of life and ability to function during migraine attacks[5]

Safety and Side Effects

Rimegepant has been generally well-tolerated in clinical trials. However, like all medications, it can cause side effects. Some of the most commonly reported side effects include:

  • Nausea
  • Nasopharyngitis (inflammation of the nose and throat)
  • Upper respiratory tract infections
  • Urinary tract infections[1]

Researchers are also monitoring for any potential liver-related side effects, although these appear to be rare[2].

Ongoing Research

Several clinical trials are currently underway to further investigate the use of rimegepant. These studies are looking at:

  • Long-term safety and effectiveness[4]
  • Use in specific populations, such as adolescents with chronic migraine[5]
  • Effectiveness for menstrual migraine[6]
  • Use in patients who can’t take other migraine medications called triptans[7]
  • Potential use for cluster headaches[3]

These ongoing studies will help to provide more information about the best ways to use rimegepant and which patients might benefit most from this medication.

Aspect Details
Drug Name Rimegepant (also known as Nurtec ODT, BHV-3000, PF-07899801)
Drug Class Calcitonin gene-related peptide (CGRP) receptor antagonist
Formulation 75 mg orally disintegrating tablet (ODT)
Indications Studied Acute migraine treatment, Migraine prevention
Patient Populations Adults with episodic and chronic migraine, Adolescents with chronic migraine, Patients unsuitable for triptans
Key Efficacy Measures Reduction in monthly migraine days, Pain relief at 2 hours, 50% responder rate
Safety Monitoring Adverse events, Liver function tests, Cardiovascular effects
Quality of Life Assessments Migraine-Specific Quality of Life Questionnaire, Headache Impact Test, Migraine Disability Assessment
Special Interest Areas Menstrual migraines, Long-term safety and efficacy, Use in patients with prior treatment failures

Ongoing Clinical Trials on Rimegepant

  • Study of Rimegepant for Prevention of Menstrual Migraine in Women Aged 18-45 Years

    Recruiting

    3 1 1
    Investigated drugs:
    Denmark Germany Italy The Netherlands Poland Spain
  • A study to evaluate the effect of rimegepant in patients with migraine and obesity

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria
  • Study on Sumatriptan and Rimegepant for Treating Nitroglycerin-Induced Headaches in Patients with Episodic Migraine

    Recruiting

    3 1 1 1
    Spain
  • Study on Rimegepant for Preventing Migraines in Children and Teens Aged 6 to 17

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Poland Spain
  • Study on the Long-Term Safety of Rimegepant for Treating Acute Migraine in Children and Adolescents Aged 6 to 17 Years

    Recruiting

    3 1 1 1
    Investigated drugs:
    Poland Spain
  • Study on Rimegepant for Treating Acute Migraine in Children and Adolescents Aged 6 to 17 Years

    Recruiting

    3 1 1
    Investigated drugs:
    Poland Spain Sweden
  • Study on Rimegepant and Capsaicin for Migraine in Lean and Obese Patients

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands
  • Study on Diclofenac Potassium and Rimegepant for Treating Migraine in Patients

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark
  • Study on Rimegepant for Treating Migraine in Adults Who Cannot Use Triptans

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Denmark Finland France Germany +4
  • Study on Rimegepant for Preventing Migraines in Adults with Poor Response to Oral Preventive Medications

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Denmark Finland Germany Italy +3

Glossary

  • Calcitonin gene-related peptide (CGRP): A protein in the body involved in pain signaling and inflammation, particularly important in migraine headaches.
  • Episodic migraine: A pattern of migraine where a person experiences fewer than 15 headache days per month.
  • Chronic migraine: A condition where a person has 15 or more headache days per month, with at least 8 of those days having migraine features, for more than 3 months.
  • Orally disintegrating tablet (ODT): A type of tablet designed to dissolve quickly in the mouth without needing water to swallow.
  • Acute treatment: Medication taken to relieve symptoms once a migraine attack has started.
  • Preventive treatment: Medication taken regularly to reduce the frequency and severity of migraine attacks.
  • Double-blind study: A research design where neither the participants nor the researchers know who is receiving the actual treatment versus a placebo.
  • Placebo: An inactive substance that looks like the medication being tested but has no therapeutic effect.
  • Open-label extension: A phase of a clinical trial where all participants receive the active treatment, often following a double-blind phase.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it is related to the treatment being studied.
  • Quality of life: A measure of a person's overall well-being and ability to function in daily life.
  • Migraine with aura: A type of migraine where a person experiences sensory disturbances (like visual changes) before or during the headache phase.
  • Medication overuse headache: A condition where frequent use of pain medications for headaches can lead to more frequent headaches.

References

  1. https://clinicaltrials.gov/study/NCT06409832
  2. https://clinicaltrials.gov/study/NCT05810038
  3. https://clinicaltrials.gov/study/NCT05264714
  4. https://clinicaltrials.gov/study/NCT05207865
  5. https://clinicaltrials.gov/study/NCT06616194
  6. https://clinicaltrials.eu/trial/study-of-rimegepant-for-prevention-of-menstrual-migraine-in-women-aged-18-45-years/
  7. https://clinicaltrials.gov/study/NCT05509400